KALA BIO, Inc.

Listed Company

KALACIK 0001479419NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

—

Total Assets

$9.49M

Equity

$7.00M

Shares Out

18.59M

Op. Cash Flow

$-31.99M

KALA$0.77−86.98% · past yearDBEQ Basic

Daily closing prices

Business

KALA BIO, Inc. is a biopharmaceutical company in strategic transition. The company evaluates commercialization of Researgency, an on-premises artificial intelligence infrastructure platform for biotechnology and pharmaceutical research. Historically, KALA BIO developed therapies for rare eye diseases; its lead program KPI-012 was discontinued after failing primary endpoints in a Phase 2b trial. The company pursues monetization of its MSC-S biologics platform and intellectual property through licensing or partnerships, and commercialization of Researgency as a platform-as-a-service offering.

Summary from 10-K filed 2026-04-15

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
General and administrative	24	18	21	—	—
Research and development	19	22	19	18	12
(Gain) loss on fair value remeasurement of contingent consideration	−5	549,000	740,000	−288,000	—
Impairment of right-of-use assets	1	—	—	—	—
Total costs and expenses	39	41	40	86	141
Loss from operations	−39	−41	−40	−82	−130
Interest income	1	2	3	664,000	104,000
Interest expense	−3	−6	−6	—	—
Grant income	3	6	5	—	—
Gain on extinguishment of debt	6	—	—	−3	−5
Other income (expense), net	5	—	−4	−926,000	—
Total other income (expense)	12	2	−3	37	−12
Net loss	−27	−39	−42	−45	−143
Net loss per share attributable to common stockholders-basic (in dollar per share)	−3.31	−10.15	−17.35	−29.48	−108.32
Net loss per share attributable to common stockholders-diluted (in dollar per share)	−3.31	−10.15	−17.35	−29.48	−108.32
Weighted average shares outstanding-basic (in shares)	8	4	2	2	1
Weighted average common shares outstanding -diluted (in shares)	8	4	2	2	1
Total comprehensive loss	−27	−39	−42	−45	−143

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	8	51	51	70	92
Prepaid expenses and other current assets	2	2	2	8	6
Total current assets	9	53	53	86	124
Property and equipment, net	—	749,000	753,000	400,000	3
Right-of-use assets	—	2	2	16,000	1
Other long-term assets	—	246,000	301,000	462,000	1
Total assets	9	55	56	87	139
Accounts payable	986,000	628,000	919,000	3	5
Accrued expenses and other current liabilities	2	5	6	—	—
Deferred grant income	—	637,000	1	—	—
Current portion of lease liabilities	—	380,000	334,000	13,000	711,000
Current portion of long-term debt	—	10	—	5	—
Total current liabilities	2	17	8	26	37
Long-term lease liabilities	—	1	2	—	548,000
Long-term debt, net of current portion	—	20	34	38	79
Long-term contingent consideration	—	5	4	4	5
Total long-term liabilities	—	26	40	42	85
Total liabilities	2	43	48	68	123
Commitments and Contingencies (Note 14)	—	—	—	—	—
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of December 31, 2025 and 2024	1,000	—	—	—	—
Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 27,849,725 and 6,091,182 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	28,000	6,000	3,000	2,000	1,000
Additional paid-in capital	702	680	637	606	559
Accumulated deficit	−695	−668	−629	−587	−542
Total stockholders' equity	7	12	8	19	17
Total liabilities and stockholders' equity	9	55	56	87	139

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−27	−39	−42	−45	−143
Depreciation and amortization	317,000	259,000	303,000	537,000	975,000
Non-cash operating lease cost	280,000	334,000	171,000	439,000	1
Amortization of debt discount and other non-cash interest	−667,000	1	1	1	2
Stock-based compensation	7	8	7	7	16
Issuance of Common Stock for service rendered	2	—	—	—	—
Issuance of Common Stock for Settlement Agreements	524,000	—	—	—	—
Loss on sale or disposal of property and equipment	549,000	—	—	—	—
Other non-cash losses	—	129,000	−4	76,000	173,000
Prepaid expenses and other current assets	−317,000	359,000	6	−2	−3
Other long-term assets	144,000	—	−144,000	—	—
Accounts payable	358,000	−291,000	−2	−2	3
Accrued expenses and other current liabilities	−4	−2	−2	−12	2
Lease liabilities and other long-term liabilities	−2	−319,000	−13,000	−344,000	−689,000
Net cash used in operating activities	−32	−29	−28	−79	−108
Purchases of property and equipment and other assets	−15,000	−208,000	−610,000	−313,000	−886,000
Net cash used in investing activities	−15,000	−208,000	−429,000	63	71
Payment of principal and payment fee on debt	−22	−5	−10	−40	−78
Payment of issuance costs from issuance of common stock and Series I preferred stock	−120,000	—	—	—	—
Proceeds from issuance of Series AA preferred stock	2	—	—	—	—
Proceeds from issuance of common stock and Series H preferred stock, net of issuance costs of $218	—	12	—	—	—
Proceeds from common stock offerings, net of offering costs of $866	9	3	19	1	41
Proceeds from issuance of common stock and Series I preferred stock	—	11	—	—	—
Contingent consideration related to Combangio acquisition	—	−119,000	−2	—	—
Payment of principal on finance lease	−92,000	−45,000	—	−39,000	−35,000
Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan	73,000	77,000	46,000	301,000	2
Net cash (used in) provided by financing activities	−12	30	9	−8	43
Net (decrease) increase in cash and cash equivalents:	−44	286,000	−20	−24	5
Issuance of common stock to satisfy service contract in additional paid-in capital	2	29,000	—	—	—
Cash paid for interest	3	5	5	6	7
Right-of-use assets obtained in exchange of finance lease obligations	—	160,000	2	424,000	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is KALA BIO, Inc.'s CIK number?

KALA BIO, Inc.'s SEC CIK number is 0001479419 (1479419). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find KALA BIO, Inc.'s SEC filings?

All of KALA BIO, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did KALA BIO, Inc. last report earnings?

KALA BIO, Inc. (KALA) most recently filed an earnings 8-K with the SEC on Aug 8, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001558370-25-010850). This is KALA BIO, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is KALA BIO, Inc.'s most recent earnings 8-K?

KALA BIO, Inc.'s latest earnings 8-K (Item 2.02) was filed Aug 8, 2025 under accession 0001558370-25-010850. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View KALA BIO, Inc.'s latest earnings 8-K →
Look up any company's CIK number →